Santé log

Vireo Growth Inc. Enters into Definitive Agreement to Acquire Certain Assets of PharmaCann Inc.

Parties also enter into Management Services Agreement through closing which is expected in 1H’26 ...
Santé log

Medline Announces Pricing of Upsized Initial Public Offering

Medline Inc. (“Medline”) announced today the pricing of its upsized initial public offering of 216,034,482 shares of its Class A common stock, at a public offering price of $29.00 per share. Medline ...
Santé log

Clover Health to Participate in Upcoming J.P. Morgan 2026 Healthcare Conference

WILMINGTON, Del., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that its Chief Executive Officer, ...
Santé log

Galecto, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Galecto, Inc. (the “Company” or “Galecto”) (Nasdaq: GLTO) today announced that the Company’s Board of Directors approved the grant of non-qualified stock options to purchase 312,535 shares of the ...
Santé log

BBOT to Present at the 44th Annual J.P. Morgan Healthcare Conference

A live webcast of the presentation will be accessible on the “ Events ” page of the BBOT website at https://investors.bbotx.com/news-events/events. A replay of the webcast will be available for at ...
Santé log

MAIA Biotechnology Announces $1.51 Million Private Placement

The gross proceeds from the offering are expected to be approximately $1.51 million, prior to offering expenses payable by the Company. The Company intends to use the net proceeds from the offering ...
Santé log

Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar Highlighting Positive Phase 3 HOPE-3 Topline Results in Duchenne Muscular Dystrophy

Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics, today announced that Parent Project Muscular Dystrophy (PPMD) will ...
Santé log

DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years

DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4- ...
Santé log

HUTCHMED Initiates Global Clinical Development of ATTC Candidate HMPL-A251 in Patients with Solid Tumors

Simultaneous China and global clinical development strategy to expedite development process — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ...
Santé log

Solid Biosciences Announces Duchenne Muscular Dystrophy Added to National Recommended Uniform Screening Panel by the U.S. Department of Health and Human Services

Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today shared that the U.S.
Santé log

Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that on ...
Santé log

FibroBiologics Announces Closing of $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

The aggregate gross proceeds to the Company from the offering were approximately $1.7 million, before deducting the placement agent’s fees and other offering expenses payable by the Company. The ...